High Free Cash Flow Stocks
NBIX is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price & Overview
NASDAQ:NBIX • US64125C1099
Current stock price
128.89 USD
-2.75 (-2.09%)
At close:
128.89 USD
0 (0%)
After Hours:
The current stock price of NBIX is 128.89 USD. Today NBIX is down by -2.09%. In the past month the price increased by 0.87%. In the past year, price increased by 41.84%.
NBIX Key Statistics
52-Week Range92.31 - 160.18
Current NBIX stock price positioned within its 52-week range.
1-Month Range125.11 - 134.2
Current NBIX stock price positioned within its 1-month range.
- Market Cap
- 12.935B
- P/E
- 27.66
- Fwd P/E
- 20.82
- EPS (TTM)
- 4.66
- Dividend Yield
- N/A
NBIX Stock Performance
Today
-2.09%
1 Week
-2.06%
1 Month
+0.87%
3 Months
-5.08%
Longer-term
6 Months -5.66%
1 Year +41.84%
2 Years -6.29%
3 Years +27.56%
5 Years +36.41%
10 Years +182.78%
NBIX Stock Chart
NBIX Stock Screens
NBIX currently appears in the following ChartMill screener lists.
Fastest Growing Stocks
NBIX is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
Revenue Growth Leaders
NBIX is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
NBIX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX is one of the better performing stocks in the market, outperforming 71.6% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NBIX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NBIX. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NBIX Earnings
On February 11, 2026 NBIX reported an EPS of 1.48 and a revenue of 805.50M. The company missed EPS expectations (-22.89% surprise) and missed revenue expectations (-0.28% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 11, 2026
PeriodQ4 / 2025
EPS Reported$1.48
Revenue Reported805.5M
EPS Surprise -22.89%
Revenue Surprise -0.28%
NBIX Forecast & Estimates
36 analysts have analysed NBIX and the average price target is 179.79 USD. This implies a price increase of 39.49% is expected in the next year compared to the current price of 128.89.
For the next year, analysts expect an EPS growth of 32.86% and a revenue growth 21.05% for NBIX
Analysts
Analysts84.44
Price Target179.79 (39.49%)
EPS Next Y32.86%
Revenue Next Year21.05%
NBIX Groups
Sector & Classification
NBIX Financial Highlights
Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 4.66. The EPS increased by 41.64% compared to the year before.
Income Statements
Revenue(TTM)2.86B
Net Income(TTM)478.60M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.73% | ||
| ROA | 10.33% | ||
| ROE | 14.71% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%48%
Sales Q2Q%28.33%
EPS 1Y (TTM)41.64%
Revenue 1Y (TTM)21.45%
NBIX Ownership
Ownership
Inst Owners100.45%
Shares100.36M
Float98.55M
Ins Owners1.11%
Short Float %3.91%
Short Ratio3.49
NBIX Latest News, Press Relases and Analysis
3 days ago - By: Chartmill
18 days ago - By: Chartmill
NBIX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NBIX
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
IPO: 1996-05-23
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA 92130 US
CEO: Kevin C. Gorman
Employees: 2000
Phone: 18586177600
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What does NBIX do?
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
What is the current price of NBIX stock?
The current stock price of NBIX is 128.89 USD. The price decreased by -2.09% in the last trading session.
Does NEUROCRINE BIOSCIENCES INC pay dividends?
NBIX does not pay a dividend.
How is the ChartMill rating for NEUROCRINE BIOSCIENCES INC?
NBIX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for NBIX stock?
36 analysts have analysed NBIX and the average price target is 179.79 USD. This implies a price increase of 39.49% is expected in the next year compared to the current price of 128.89.
What is the employee count for NBIX stock?
NEUROCRINE BIOSCIENCES INC (NBIX) currently has 2000 employees.
What is the ownership structure of NEUROCRINE BIOSCIENCES INC (NBIX)?
You can find the ownership structure of NEUROCRINE BIOSCIENCES INC (NBIX) on the Ownership tab.